Video
Dr. Balar on Combinations with Pembrolizumab for Urothelial Cancer
Author(s):
Arjun V. Balar, MD, assistant professor of Medicine, Division of Hematology and Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses combinations with pembrolizumab (Keytruda) for patients with urothelial carcinoma.
Arjun V. Balar, MD, assistant professor of Medicine, Division of Hematology and Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses combinations with pembrolizumab (Keytruda) for patients with urothelial carcinoma.
There are several combination strategies that are noteworthy for pembrolizumab, explains Balar. There is a combination of pembrolizumab, radiation, and chemotherapy in patients with localized muscle invasive bladder cancer, which is currently being investigated.
Additionally, there is a randomized phase III trial of pembrolizumab with epacadostat versus single-agent pembrolizumab which many are excited to see the results of, states Balar.
